CY1120082T1 - Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων - Google Patents

Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων

Info

Publication number
CY1120082T1
CY1120082T1 CY20181100039T CY181100039T CY1120082T1 CY 1120082 T1 CY1120082 T1 CY 1120082T1 CY 20181100039 T CY20181100039 T CY 20181100039T CY 181100039 T CY181100039 T CY 181100039T CY 1120082 T1 CY1120082 T1 CY 1120082T1
Authority
CY
Cyprus
Prior art keywords
aminoglycosides
genetic disorders
therapeutic treatment
alkyl
group
Prior art date
Application number
CY20181100039T
Other languages
Greek (el)
English (en)
Inventor
Timor Baasov
Dana Atia-Glikin
Jeyakumar Kandasamy
Valery Belakhov
Original Assignee
Technion Research & Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research & Development Foundation Ltd. filed Critical Technion Research & Development Foundation Ltd.
Publication of CY1120082T1 publication Critical patent/CY1120082T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D79/00Kinds or details of packages, not otherwise provided for
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/228Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
    • C07H15/23Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with only two saccharide radicals in the molecule, e.g. ambutyrosin, butyrosin, xylostatin, ribostamycin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY20181100039T 2010-11-18 2018-01-15 Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων CY1120082T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41495610P 2010-11-18 2010-11-18
PCT/IL2011/000889 WO2012066546A1 (en) 2010-11-18 2011-11-17 Aminoglycosides and uses thereof in treating genetic disorders

Publications (1)

Publication Number Publication Date
CY1120082T1 true CY1120082T1 (el) 2018-12-12

Family

ID=45390144

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100039T CY1120082T1 (el) 2010-11-18 2018-01-15 Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων

Country Status (18)

Country Link
US (7) US8895519B2 (enExample)
EP (2) EP2640734B1 (enExample)
JP (3) JP5960712B2 (enExample)
CA (1) CA2816789C (enExample)
CY (1) CY1120082T1 (enExample)
DK (1) DK2640734T3 (enExample)
ES (2) ES2833938T3 (enExample)
HR (1) HRP20180056T1 (enExample)
HU (1) HUE036248T2 (enExample)
IL (3) IL266495B (enExample)
LT (1) LT2640734T (enExample)
NO (1) NO2640734T3 (enExample)
PL (1) PL2640734T3 (enExample)
PT (1) PT2640734T (enExample)
RS (1) RS56739B1 (enExample)
SI (1) SI2640734T1 (enExample)
SM (1) SMT201800019T1 (enExample)
WO (1) WO2012066546A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2640734T1 (en) * 2010-11-18 2018-02-28 Technion Research & Development Foundation Ltd. Aminoglycosides and their uses in the treatment of genetic disorders
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP2017516835A (ja) * 2014-06-05 2017-06-22 エロックス ファーマシューティカルズ リミテッド レット症候群治療におけるアミノグリコシド類縁体の使用
EP3344641A4 (en) * 2015-09-02 2019-09-18 Eloxx Pharmaceuticals Ltd. AMINO-LIKES DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF GENETIC DISEASES
US11306115B2 (en) 2015-09-02 2022-04-19 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3350194A4 (en) 2015-09-02 2019-04-24 Eloxx Pharmaceuticals Ltd. AMINO-LIKES DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF GENETIC DISEASES
WO2017118968A1 (en) * 2016-01-05 2017-07-13 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
CN117466958A (zh) * 2017-03-15 2024-01-30 Eloxx制药有限公司 假三糖氨基糖苷及其中间体的大规模制备
WO2019237076A1 (en) * 2018-06-07 2019-12-12 Eloxx Pharmaceuticals, Inc. Methods, compositions, and kits for inducing readthrough
KR102067477B1 (ko) * 2018-06-20 2020-01-17 고려대학교 산학협력단 스킬로이노사민을 포함하는 아미노사이클리톨 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물
AU2019387385A1 (en) * 2018-11-29 2021-07-08 Eloxx Pharmaceuticals Methods, compositions, and kits for treating ocular diseases
WO2021061873A1 (en) * 2019-09-23 2021-04-01 Eloxx Pharmaceuticals, Inc. Methods, compositions, and kits for treating polycystic kidney disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5960712A (ja) 1982-09-30 1984-04-06 Toshiba Corp デ−タ判別装置
WO2005078099A1 (en) 2004-02-17 2005-08-25 The Hospital For Sick Children Mecp2e1 gene
EP2390255B1 (en) * 2006-04-03 2016-07-13 Technion Research & Development Foundation Ltd. Novel aminoglycosides and uses thereof in the treatment of genetic disorders
SI2640734T1 (en) * 2010-11-18 2018-02-28 Technion Research & Development Foundation Ltd. Aminoglycosides and their uses in the treatment of genetic disorders
JP2017516835A (ja) * 2014-06-05 2017-06-22 エロックス ファーマシューティカルズ リミテッド レット症候群治療におけるアミノグリコシド類縁体の使用

Also Published As

Publication number Publication date
IL266495A (en) 2019-07-31
ES2833938T3 (es) 2021-06-16
US20170182078A1 (en) 2017-06-29
SI2640734T1 (en) 2018-02-28
CA2816789C (en) 2018-12-11
PT2640734T (pt) 2018-01-22
US9175029B2 (en) 2015-11-03
US20210228608A1 (en) 2021-07-29
EP2640734A1 (en) 2013-09-25
IL266495B (en) 2020-09-30
US20130237489A1 (en) 2013-09-12
CA2816789A1 (en) 2012-05-24
WO2012066546A1 (en) 2012-05-24
JP6758338B2 (ja) 2020-09-23
US11865128B2 (en) 2024-01-09
EP3296311A1 (en) 2018-03-21
HK1248709A1 (en) 2018-10-19
JP2016121168A (ja) 2016-07-07
US9616079B2 (en) 2017-04-11
JP5960712B2 (ja) 2016-08-02
ES2655916T3 (es) 2018-02-22
HRP20180056T1 (hr) 2018-02-09
US20180200276A1 (en) 2018-07-19
JP2013542981A (ja) 2013-11-28
IL284067A (en) 2021-07-29
US10398718B2 (en) 2019-09-03
PL2640734T3 (pl) 2018-04-30
US9943533B2 (en) 2018-04-17
JP2018123135A (ja) 2018-08-09
SMT201800019T1 (it) 2018-03-08
EP3296311B1 (en) 2020-09-30
LT2640734T (lt) 2018-02-12
DK2640734T3 (en) 2018-01-22
RS56739B1 (sr) 2018-03-30
HUE036248T2 (hu) 2018-06-28
IL277063A (en) 2020-10-29
US20140357590A1 (en) 2014-12-04
US20160074425A1 (en) 2016-03-17
NO2640734T3 (enExample) 2018-03-17
EP2640734B1 (en) 2017-10-18
US20190224226A9 (en) 2019-07-25
IL277063B (en) 2021-07-29
US8895519B2 (en) 2014-11-25
US20200078386A1 (en) 2020-03-12
IL284067B (en) 2022-03-01
US10973839B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
CY1120082T1 (el) Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
CY1122703T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
WO2020227549A8 (en) MODULATORS OF THR-β AND METHODS OF USE THEREOF
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
EP4600271A3 (en) Bioactive molecule conjugate, preparation method and use thereof
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2018102452A3 (en) Using substituted pyrazole compounds for treatment of hyperproliferative diseases
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX380928B (es) Inhibidores de kras g12c.
EA201291073A1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
BR112015023412A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
IN2015DN01119A (enExample)